{
    "root": "6718ab7c-7205-4927-4055-0ce76dfca7ac",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Dasatinib",
    "value": "20250225",
    "ingredients": [
        {
            "name": "dasatinib",
            "code": "RBZ1571X5H"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "GLYCERYL MONO- AND DICAPRYLOCAPRATE",
            "code": "U72Q2I8C85"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "Dasatinib",
            "code": "RBZ1571X5H"
        }
    ],
    "indications": "Dasatinib tablets are indicated for the treatment of adult patients with\n                  \n                     \n                        newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\n                     \n                     \n                        chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.\n                     \n                     \n                        Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.\n                     \n                  \n                  Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with\n                  \n                     \n                        Ph+ CML in chronic phase.\n                     \n                     \n                        newly diagnosed Ph+ ALL in combination with chemotherapy.",
    "contraindications": "Chronic phase CML in adults: 100 mg once daily. ( 2 ) Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg once daily. ( 2 ) Chronic phase CML and ALL in pediatrics: starting dose based on body weight. ( 2 ) Administer orally, with or without a meal. Do not crush, cut, or chew tablets. ( 2 )",
    "warningsAndPrecautions": "How Supplied\n                  \n                  Dasatinib tablets are available as described in Table 21.\n                  \n                     Table 21:        Dasatinib Tablets Trade Presentations\n                  \n                  \n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              NDC Number\n                           \n                           \n                              Strength\n                           \n                           \n                              Description\n                           \n                           \n                              Tablets per Bottle\n                           \n                        \n                        \n                           70377-083-11\n                           20 mg\n                           White to off-white, biconvex, round, film-coated tablet with “D8” debossed on one side and plain on the other side and free from physical defects.\n                           60\n                        \n                        \n                           70377-084-11\n                           50 mg\n                           White to off-white, biconvex, oval, film-coated tablet with “D6”debossed on one side and plain on the other side and free from physical defects.\n                           60\n                        \n                        \n                           70377-085-11\n                           70 mg\n                           White to off-white, biconvex, round, film-coated tablet with “D4” debossed on one side and plain on the other side and free from physical defects.\n                           60\n                        \n                        \n                           70377-086-11\n                           80 mg\n                           White to off-white, biconvex, triangle, film-coated tablet with “D3” debossed on one side and plain on the other side and free from physical defects.\n                           30\n                        \n                        \n                           70377-087-11\n                           100 mg\n                           White to off-white, biconvex, oval, film-coated tablet with “D2” debossed on one side and plain on the other side and free from physical defects.\n                           30\n                        \n                        \n                           70377-088-11\n                           140 mg\n                           White to off-white, biconvex, round, film-coated tablet with “D1” debossed on one side and plain on the other side and free from physical defects.\n                           30\n                        \n                     \n                  \n                  \n                     Storage\n                  \n                  Dasatinib tablets should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].\n                  This package is child-resistant.\n                  \n                     Handling and Disposal\n                  \n                  Dasatinib tablet is an antineoplastic product. Follow special handling and disposal procedures.1\n                  \n                  Personnel who are pregnant should avoid exposure to crushed or broken tablets.\n                  Dasatinib tablets consist of a core tablet, surrounded by a film coating to prevent exposure of healthcare professionals to the active substance. The use of latex or nitrile gloves for appropriate disposal when handling tablets that are inadvertently crushed or broken is recommended, to minimize the risk of dermal exposure.",
    "adverseReactions": "None."
}